In the context of third-line therapy for GC, the KEYNOTE-012 trial assessed the efficacy of immune checkpoint inhibitors (ICIs), particularly pembrolizumab, in patients with PD-L1-positive recurrent or metastatic GC or GEJ cancer (GEJC). This evidence concerns the gene CD274 and gastric cancer.